SecBot SecBot
SC 13G ·Filed Nov 10, 2026

SNDX

Syndax Pharmaceuticals Inc
NEUTRAL
Impact 3/10
Horizonimmediate Processed6d 17h ago SEC0000093751-26-000728
Passive investor 5%+ stake
Actionable Insight • Neutral

State Street's passive stake increase is routine for a large index fund manager. Monitor the next 13F filing for any material changes in institutional positioning, but this filing alone does not signal a shift in investment thesis.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$9.49
T+0 close · Nov 10, 2026 · via day close
Latest settled
+1.05%
T+1 · $9.59
Vs SPY
−0.27%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $9.49entry
  2. T+1 · 6d ago +1.05%α −0.27% · $9.59
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

State Street Corp filed a Schedule 13G disclosing a 5.2% passive stake in Syndax Pharmaceuticals as of September 30, 2026, representing 4,653,172 shares. This is an amendment to its prior 13G filed in August 2026, showing a slight increase in holdings. The filing confirms a passive investment intent with no control or activist purpose.

Key Financial Metrics

Stake
5.2%
Investor
STATE STREET CORP
Investor Type
mutual fund

Key Facts

  • State Street Corp disclosed beneficial ownership of 4,653,172 shares of Syndax Pharmaceuticals common stock
  • Stake represents 5.2% of shares outstanding as of September 30, 2026
  • Filing is an amendment to a prior 13G filed August 7, 2026
  • State Street certifies passive investment intent under Rule 13d-1(b)
  • State Street is a top institutional holder per Q2 2026 13F data with $124M position

Financial Impact

State Street's stake is valued at approximately $44.6M based on the current $858M market cap and 5.2% ownership

Risk Factors

  • No activist intent or control purpose disclosed
  • Passive 13G filing; no imminent catalyst from this holder

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000093751-26-000728
Document: 0000093751-26-000728-index.html0000093751-26-000728
Document: 0000093751-26-000728.txt0000093751-26-000728

Track record

16 reports on SNDX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $9.49 Now $9.13 −3.79% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  4. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  5. Nov 2, 202614d ago Press Release Neutral 2/10 No price data
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
  7. Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
  8. Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
  9. Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
  10. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 7h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026